The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
AACR 2017 | Poster 1318/19 – Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma genome-wide association study finds an association with chromosomes 6 and 14
On Monday 3rd April, during the American Association for Cancer Research (AACR) 2017 annual meeting, a poster (1318 / 19) by Mary L. McMaster, from NCI-DCEG, Bethesda, MD, et al. titled “A genome-wide association study of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma demonstrates association with chromosomes 6 and 14” was presented.
The group aimed to find common genetic aberrations resulting in susceptibility to Waldenström Macroglobulinemia (WM). They carried out a two-stage Genome-Wide Association study (GWAS) which included more than 450 WM cases and 4,300 controls of European ancestry. Stage 1 (discovery) included 217 cases of WM (40% familial) and 3,798 controls. Stage 2 (replication) included 269 WM or LPL cases (4% familial) and 571 controls.
Key Highlights:
- Two novel loci on chromosomes 6 and 14 associated with WM/LPL
- Stage 1 set enriched for familial cases, and strongest signals replicated in mostly non-familial dataset
- Preliminary results confirm replication of the chromosome 6 locus
- EXOC2, the strongest signal (chromosome 6), is associated with DLBCL; common genetic mechanisms potentially contribute to development of heterogeneous Lymphoma subsets
- Chromosome 14 signal found in intergenic region near T-Cell Leukemia (TCL) gene family
- TCL1A is potential candidate; expression is differentiation stage-specific in B-cells and is aberrantly expressed in mature B-cell malignancies including WM
The poster was concluded by stating that this group’s results provide some understanding of the underlying genetic basis of WM susceptibility.
References